Mesothelioma Online Help

Actos and Bladder Cancer : Traditionally, the surgery is performed through a lower abdominal incision in the midline from just below the umbilicus (i.e., “belly button”). Hospitalization for this procedure is generally between 5 and 10 days, and up to 6 weeks are needed for complete recovery. In recent years minimally invasive surgical approaches that replicate the technique of open radical cystectomy have been developed. Both laparoscopic and robotic-assisted radical cystectomies are currently being performed at highly specialized cen­ters. The principles of the surgery are the same, but the procedure is performed through smaller incisions using laparoscopic instruments. Using robotic assistance, your surgeon is able to perform complex operations with higher precision, under magnification. These approaches offer die potential advantage of a shorter recovery time, less blood loss, and less postoperative pain,

More information on Actos and Bladder Cancer

A pelvic lymph node dissection should be performed at the time of your surgery. This involves removal of the lymph node tissue in the most common areas of bladder cancer metastasis (spread of the cancer). The pelvic lymph node dissection has two important roles: to stage the cancer and to guide therapy. Individuals who are found to have cancer in the lymph nodes at the time of surgery generally require additional therapy such as chemotherapy. Studies have shown that up to 30 percent of patients with disease- positive lymph nodes who undergo a pelvic lymph node dissection will be free of disease at 5 years. Although there is debate among urologists as to exactiy how extensive ofapelvic lymph node dissection should be performed, there is no de­bate that one should be performed. Although a pelvic lymph node dissection can add an additional 30-90 minutes to your procedure time, there is little additional morbidity associ­ated when performed by an experienced surgeon.

Information from other sources on Actos and Bladder Cancer

Regardless of the approach, anyone who undergoes a radical cystectomy will require a form of urinary diversion because the bladder will no longer be there to store urine. This can have a significant psychological and functional impact on an individual’s quality of life. Patients are often hesitant to undergo definitive surgery because of the anxiety associated with long-term urinary diversion. There are two main types of urinary diversion: continent and noncontinent. Both forms require surgically removing a segment of bowel (most commonly the small bowel) from your gastrointestinal (GI) tract and plugging the ureter from each kidney into this segment of bowel to provide drainage of urine. Noncontinent diversions (ileal conduit) are those in which the piece of bowel is brought up through the abdominal wall to a stoma and the urine drains contin­uously into a drainage bag. This is die most common type of urinary diversion performed in the United States. This procedure requires approximately 8 to 10 centimeters (3 to 4 inches) of small bowel, which is far less than that used for continent urinary diversions. Although the obvious dis­advantage of this procedure is its lack of continence and need for a continuous drainage bag, it has less short- and long-term complications than that of the continent diver­sion. An external urinary drainage appliance is very well tolerated and patients adapt to them very quickly.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Actos and Bladder Cancer: Due to the ease of obtaining voided urine specimens, bladder cancer is on the forefront of developing tumor markers. Drs. McNeil, Ekwenna, and Getzenberg take an in depth look at various tumor markers and molecular signatures of bladder cancer in Chap. 6. Although several new tumor markers for bladder cancer are discovered each year and are the subject of numerous review articles, only few reviews are written on the subject of healthcare cost associated with bladder cancer diagnosis, screening, and surveillance. Chapter 7 by Yair Lotan is devoted to the subject of cost associated with bladder cancer detection and surveillance in the general versus high-risk population and using noninvasive techniques such as hematuria detection and tumor markers.

More information on Actos and Bladder Cancer

Prognostic markers and molecular nomograms involving proteomics and genom­ics are highly researched and some of the new emerging areas in bladder cancer. In Chap. 8, Dr. Habuchi focuses on seven different classes of molecules ranging from cell adhesion molecules to genetic alterations, which have been investigated for pre­dicting disease progression, response to treatment (local versus systemic control of the disease),

and survival. Chapter 9 by Smith and Theodorescu dwells on a novel idea of molecular nomograms for personalized medicine. While Chap. 8 includes information on individual markers, this chapter focuses on multiplexing of molecular biomarkers to predict response to therapy. Of note is COXEN or Co-expression Extrapolation) algorithm that compares microarray gene expression profiles between cell lines and patient tumors to generate signatures predictive of drug sensitivity or resistance.

Information from other sources on Actos and Bladder Cancer

Bladder cancer being a complex disease, a practical guide that provides the nec­essary facts at the fingertips is very useful and Chap. 10 by Drs. Levy and Jones provides just that for the management of nonmuscle invasive bladder cancer. Specifically the chapter provides a succinct description of epidemiology, etiology, pathophysiology, clinical and diagnostic evaluations, available molecular markers for disease, as well as the current American Urological Association Guidelines Panel Recommendations and therapies for nonmuscle invasive and recurrent blad­der cancer.Chapters 11-22 encompass clinical management of bladder cancer. Starting from the low-grade bladder cancer, Chap. 11 by Dr. William Oosterlink focuses on histology, risk factors, and diagnosis and detection of low-grade tumors in the blad­der and the upper tract, whereas Chap. 12 by Allaparthi and Balaji covers the clini­cal management of low-grade tumors.

Intravesical chemotherapy or immunotherapy (Bacillus Calmette-Guerin [BCG]) are key adjuvant therapies for the control of high-grade nonmuscle invasive bladder cancer. In Chap. 13, Drs. Adiyat, Katkoori, and Soloway is a review of indications and practical aspects of administration of intravesical chemotherapy, properties, efficacy, and side effects of various intravesical agents, and newer methods improv­ing the efficacy of the intravesical drugs. Although, many reviews have been writ­ten on intravesical BCG therapy, the review by Drs. Bishay, Park, and Hemstreet is unique because of the depth of discussion on the mechanism of action of BCG in animal versus cell culture models, and the involvement of the immune system and inflammatory cytokines/chemokines in mediating response to BCG.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : An intravenous pyelogram (IVP) is an X-ray study that shows the general outline of the kidneys and better detail of the collecting system than an ultra­sound. X-ray contrast is given to the patient intra­venously. The kidneys then filter and concentrate the contrast, creating an image on an X-ray taken a few minutes after the injection is given. A small tumor or stone inside the collecting system can be seen as a dark spot inside the collecting system. Historically, the IVP was a common test to evaluate upper tracts. However, due to the decreased cost of CT scans and the increased availability, it has largely been replaced by CT scanning.

CT scanners use X-rays to create a detailed image of the internal organs. The scanner takes many X-rays at once and uses a computer to combine all of the images into the one picture that you see. When getting a CT scan of the kidneys, the patient is usually scanned three times. The first scan is per­formed without contrast and will reveal any kidney stones. The second scan is performed with contrast, which helps to show tumors in the kidneys. The third scan is obtained a few minutes later, after the kidney has had time to process the contrast. The contrast fills the collecting system similar to the IVP but with greater detail. A CT scan is very good for seeing tumors in both the kidneys and the col­lecting system. In addition to the ability to see the kidneys and ureters better, the CT scan allows for visualization of the entire abdomen and lymph nodes, helping to identify metastases or unrelated diseases. Over the last several years, the cost of CT scans has come down, and the availability of scan­ners to patients has increased, making the CT scan the most common upper tract study. As with the IVP test, CT scans meant to examine the kidneys

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Although ureteroscopy is not technically an “upper tract study,” it gives us the most definitive examina­tion. It is similar to cystoscopy but uses a smaller scope. In the operating room or well-equipped office, the ureteroscope is carefully passed into the ureter as it opens into the bladder. This allows the urologist to see the inside of the ureter. It is gently passed all of the way up the ureter into the kidney. Like cys­toscopy, there are both rigid and flexible uretero- scopes. The flexible scope allows doctors to see all or most of the deep corners of the collecting system within the kidney. Biopsies of any suspicious areas can be taken and sent to pathology for analysis. Although ureteroscopy provides the best view of the collecting system, it usually requires anesthesia, and there is some small risk of damage to the kidney or ureter; thus, it is usually reserved for those patients who have had an abnormal upper tract study.

Information from other sources on Actos and Bladder Cancer

Cysview (hexaminolevulinate hydrochloride, GE health­care) has recently been approved as an optical imaging agent for use in the cystoscopic detection of non-muscle invasive papillary bladder cancer among patients sus­pected or known to have lesion(s) on the basis of prior cystoscopy. When used in combination with blue light (fluorescence) cystoscopy (Karl Storz D-Light C Pho­todynamic Diagnostic [PPD] system) it identified at least 1 more noninvasive papillary bladder tumor than rou­tine cystoscopy in about one third of the patients with such tumors. It is also useful in detecting carcinoma in situ, identifying 28% more patients with carcinoma in situ than standard cystoscopy.

Urine cytology is commonly used to screen for bladder cancer in patients who have hematuria as well as to monitor for recurrences in patients who are being treated for bladder cancer. Overall, urine cytology is able to detect 40% to 60% of bladder cancers, but the ability of cytology to detect a tumor varies depending on the grade, stage, and location of the tumor. In low-grade, low- stage tumors, cytology will detect only 25% to 40% of the tumors. It will perform better as the grade and stage of the tumor increase, with the best detection rate being for carcinoma in situ. Cytology detects approximately 90% of cases of carcinoma in situ.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : A catheter is a plastic or rubber tube which is placed through the urethra into the bladder. It is kept in place by a fluid filled balloon, at the end of the catheter, which is inflated in the bladder. The tube allows for drainage of urine which may be mixed with blood after a TURBT. When small tumors are removed, a catheter is not usually required unless there is a concern that you may have difficulty urinating after the procedure because of an enlarged prostate, weak bladder or swelling of the urethra after instrumentation. After large tumors are resected, a catheter is often required. It serves the following purposes:

It allows one to monitor the amount of bleeding after surgery (although the urologist attempts to stop all bleeding, this is not always possible and bleeding may persist).

It provides for bladder irrigation if required. If much bleeding is present after surgery, it is important to avoid the possibility of blood clots forming and blocking the flow of urine. Irrigation can be done intermittently with a syringe or continuously via a 3 way catheter, which has a port for inflow and outflow of irrigant.

More information on Actos and Bladder Cancer

It keeps the bladder decompressed, which may be important if the resection was deep and bladder integrity is in question. The bladder may have been thinned markedly in the area of resection or biopsies. Decompression provides for reduced risk of leakage through the wall of the thinned bladder.

HOW UNCOMFORTABLE IS THE CATHETER?

Most individuals complain of some discomfort from their catheter. The most common complaint is a feeling of pressure in the bladder, often thought to be secondary to stimulating the bladder and resulting in a “bladder spasm”. This sensation can often be reduced markedly with medication to relax the bladder. Sometimes pain medication is also required. The catheter may also cause irritation at the opening of the urethra, which can be reduced by being sure the catheter is kept clean at this site via gently cleansing and possibly applying an antibiotic ointment to the urethral opening.

Information from other sources on Actos and Bladder Cancer

If it was placed for bleeding, generally when the bleeding slows or stops over a day or two, the catheter will be removed. If it is in for a compromised bladder wall, it may need to remain for a week or more. When the catheter is removed, the urologist simply empties the balloon that holds it in place, and then gently pulls out the catheter. There is minimal discomfort during removal and generally a smile follows once it is out.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer :

WHAT IS CANCER?

Cancer is defined as a group of diseases characterized by uncontrolled growth and spread of abnormal cells. Cells are the small building blocks of our body and most other living organisms. If the spread of these abnormal cells is not controlled, it can result in organ dysfunction and death. There are several cancers, each affecting various portions of the body. Cancer can be caused by external factors like cigarette smoking, exposure to certain chemicals, radiation, or infectious organisms. Internal factors that can lead to cancer include inherited mutations, hormones, and conditions

affecting your immune system. Mutations are permanent changes in your hereditary material, and hormones are products of certain cells in our body that influence the function of other cells.

More information on Actos and Bladder Cancer

Although scientists have been able to uncover the cause of some cancers, there is still a great deal to be learned. One may go through his or her entire life without exposure to any of the previously mentioned factors and develop cancer. Men have a higher risk of developing cancer, with a slightly less than i in 2 lifetime risk in the United States compared with 1 in 3 for women. Although cancer is more common than you may think, doctors have figured out new ways to diagnose and treat cancer. By no means is cancer a death sentence; it can be managed and a lot of people diagnosed go on to live healthy and productive lives for many years after treatment.

Information from other sources on Actos and Bladder Cancer

Epidemiology is essentially the study of factors affecting the health and illness of populations. Before moving on with our discussion about bladder cancer, it’s important to gain perspective on how many people live with bladder cancer.

There are over 1 million people throughout the world living with bladder cancer. Bladder cancer is the seventh or ninth most common cancer, depending on where you live. Most individuals with bladder cancer live in industrialized countries and geographical areas where infection with the parasite Schistosoma haematobium is common. In the United States bladder cancer is the fourth most common cancer in men and the ninth most frequently diagnosed cancer in women. The male-to-female ratio is 3 to 1. Two- thirds of cases are diagnosed in people over age So, but it

can occur very early in life. Two times as many whites will be diagnosed with bladder cancer compared with African Americans. The reasons for this are unclear.

Our use of the term or terms Actos and Bladder Cancer  is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer :

WHAT CAUSES BLADDER CANCER?

Ludwig Rehn, a German surgeon during the 19th century, is credited with the first explanation of one of the root causes of bladder cancer. He established a link between exposure to chemicals used in the production of colored textiles and the development of bladder cancer in factory workers. Although his discovery was not initially accepted, bladder cancer was soon recognized as an occupational cancer in factory workers. This may help explain the higher incidence of bladder cancer in industrialized nations.

More information on Actos and Bladder Cancer

Exposure to a number of chemicals has been associated with the development of bladder cancer. These include aniline dyes and other members of the aromatic amine family. People who work in occupations where exposure to these chemicals is common include textile workers, dye workers, rubber workers, painters, and even hairdressers. Please see Table 1-1 for a list of occupations associated with an increased risk of developing bladder cancer.

Information from other sources on Actos and Bladder Cancer

Smoking is the most common cause of bladder cancer today. It increases your risk of developing bladder cancer 2- to 4-fold compared with people who don’t smoke. The risk of bladder cancer increases with the frequency and duration of smoking. For example, someone who smokes one pack a day for 20 years has a higher risk of bladder cancer than someone who smokes a few cigarettes on weekends. When you stop smoking you can slowly decrease the risk of bladder cancer, over the course of 20-30 years. If you currently smoke, it would be best to stop smoking

Our use of the term or terms  Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer12/20/2011: The neurovascular bundles which run adjacent and adherent to the prostate can be pushed aside as the bladder and prostate are removed. This is more technically difficult compared to the standard non-nerve sparing approach. Sparing the nerves is not always possible even with the best effort. If the individual has questionable erections prior to the surgery, a nerve sparing procedure rarely leads to preservation of erections and therefore is not warranted. Extensive bladder cancer may encroach on the prostate, making a nerve sparing procedure extremely difficult if not impossible.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos Litigation , Actos FDA Recall is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos.Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos and Bladder Cancer12/20/2011: When facing the prospects of chemotherapy, it is essential to have an oncologist who can inform you fully of the potential probable effectiveness of the chemotherapy being offered. Just as importantly, the toxicities of the chemotherapy must be fully reviewed. Of course, there are no absolutes when reviewing the potential for success and failure. Each individual’s cancer is unique. Some respond better than others to chemotherapy. General statistics regarding disease regression and remission are available. Absolute numbers for the individual are not.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos Bladder Cancer, Actos Class Action Lawsuit is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos.Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com